Yihai Cao, MD, Ph.D.

AIMBE College of Fellows Class of 2021
For his pioneering contributions to angiogenesis research.

Anticancer drug effective against severe COVID-19

Via Sciencenews | May 7, 2021

A small trial with participants from Italy and China shows that the anticancer drug bevacizumab is extremely effective in reducing severe COVID-19 symptoms.

The whole world is looking for new ways to combat COVID-19.

This mainly relates to manufacturing vaccines, but pharmaceutical companies have also developed many antibody treatments to the clinical trial stage and launched them on the market.

The anticancer drug bevacizumab may be able to lend the world an unexpected helping hand. A new study shows that bevacizumab can significantly reduce severe respiratory symptoms and fever from COVID-19. It can also reduce the risk of dying from COVID-19 and alleviate a severe COVID-19 trajectory… Continue reading.


Dr. Yihai Cao to be inducted into medical and biological engineering elite

Via AIMBE | February 15, 2021

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of Yihai Cao, MD, Ph.D., to its College of Fellows. Dr. Cao was nominated, reviewed, and elected by peers and members of the College of Fellows for his pioneering contributions to angiogenesis research.

The College of Fellows is comprised of the top two percent of medical and biological engineers in the country. The most accomplished and distinguished engineering and medical school chairs, research directors, professors, innovators, and successful entrepreneurs comprise the College of Fellows. AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation and many also are members of the National Academy of Engineering, National Academy of Medicine, and the National Academy of Sciences… Continue reading.